Clinical trials: Esophagogastric Junction
Gastric Cancer
Tripletrumab Combined With Oxaliplatin and Teggio (SOX) in First-line Treatment of Gastric and Gastroesophageal Junction Adenocarcinoma
The aim population is histopathologically confirmed locally unresectable advanced recurrent or metastatic adenocarcinoma of the gastric and gastroesophageal junction.
- Trial name
- NCT04202484
- Testing
- Toripalimab combined with oxaliplatin and Tegafur,Gimeracil and Oteracil Porassium Capsules
- Volunteers
- 20 people
- Sponsor
- RenJi Hospital
Esophageal Cancer, Gastric Cancer
A Study Evaluating Safety and Efficacy of Niraparib in Patients With Previously Treated Metastatic Esophageal/Gastroesophageal Junction/Proximal Gastric Adenocarcinoma
Patients can be prescreened for the study at the time of diagnosis of locally advanced or metastatic disease by determining presence of LOH high status and/or deleterious alterations in HR pathway genes in the most recent…
- Conditions
- Esophageal Cancer, Gastric Cancer, Adenocarcinoma
- Trial name
- NCT03840967
- Testing
- Niraparib
- Where
- 4 sites in United States
- Volunteers
- 14 people
- Sponsor
- Shadia Jalal, MD
Gastric Cancer
Tislelizumab Plus Chemotherapy as Postoperative Adjuvant Therapy in Elderly Patients With LA GC/GEJC
The purpose of study is to evaluate the efficacy and safety of postoperative adjuvant chemotherapy with tislelizumab in combination with tegafur-gimeracil-oteracil potassium (S-1 therapy) or tegafur-gimeracil-oteracil potassium +…
- Trial name
- NCT06238167
- Testing
- Tislelizumab, S-1 therapy, low dose SOX therapy
- Volunteers
- 40 people
- Sponsor
- First Affiliated Hospital of Wenzhou Medical University
Clinical Stage I Esophageal Adenocarcinoma AJCC v8, Clinical Stage I Esophageal Squamous Cell Carcinoma AJCC v8
A Prospective Study of Physical Function in Adults Who Receive Systemic Therapy for Stage I-III Gastroesophageal Cancer, FAST-GO Study
This study evaluates how the treatment for gastroesophageal cancer affects physical function in patients who receive chemotherapy as part of their treatment for gastroesophageal cancer.
- Conditions
- Clinical Stage I Esophageal Adenocarcinoma AJCC v8, Clinical Stage I Esophageal Squamous Cell Carcinoma AJCC v8, Clinical Stage I Gastric Cancer AJCC v8, Clinical Stage I Gastroesophageal Junction Adenocarcinoma AJCC v8
- Trial name
- NCT07517211
- Testing
- Non-Interventional Study
- Where
- United States
- Volunteers
- 72 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Gastric Adenocarcinoma and Gastroesophageal Junction Adenocarcinoma
SHR-1701 Combined With Chemotherapy for Gastric or Gastroesophageal Junction Adenocarcinoma With Peritoneal Metastasis
This study is a prospective, randomized, two-cohort trial designed to evaluate the efficacy and safety of two regimens in the treatment of gastric or gastroesophageal junction adenocarcinoma with peritoneal metastasis: SHR-1701…
- Trial name
- NCT07384234
- Testing
- SHR-1701, Capecitabine, S-1
- Where
- 2 sites in China
- Volunteers
- 60 people
- Sponsor
- Ruijin Hospital
Adenocarcinoma
Minimally Invasive Sweet Esophagectomy for Patients With Siewert Type II Adenocarcinoma of the Esophagogastric Junction
Of the esophagogastric junction adenocarcinoma (AEG) is a 5 cm region of adenocarcinoma of the esophagus and stomach. Due to the special anatomical location, the biological behavior of esophageal cancer and gastric cancer are not…
- Trial name
- NCT02741778
- Testing
- Minimally invasive group, Open group
- Volunteers
- 120 people
- Sponsor
- Anhui Provincial Hospital
Gastric and Gastroesophageal Junction Adenocarcinoma
A Study of AK104/Placebo Plus AK109/Placebo And Paclitaxel in Gastric or Gastroesophageal Junction Adenocarcinoma
This randomized, multicenter, double-blind, phase 3 study will evaluate the efficacy and safety of the combination of cadonilimab (AK104) and pulocimab (AK109) and paclitaxel compared with paclitaxel in patients with advanced…
- Trial name
- NCT06341335
- Testing
- cadonilimab, pulocimab, paclitaxel
- Where
- China
- Volunteers
- 506 people
- Sponsor
- Akeso
Advanced/Metastatic Solid Tumors, Colorectal Cancer
A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors
This is a Phase 1/2 open-label, multi-center, multi-national study with an initial dose escalation part to determine the recommended Phase II dose (RP2D) of MCLA-158 single agent in patients with mCRC.
- Conditions
- Advanced/Metastatic Solid Tumors, Colorectal Cancer, Gastric Cancer, Gastroesophageal-junction Cancer
- Trial name
- NCT03526835
- Testing
- MCLA-158, MCLA-158 + Pembrolizumab, MCLA-158 + FOLFIRI
- Where
- 54 sites in United States, Belgium and 5 more
- Volunteers
- 560 people
- Sponsor
- Genmab
CLDN18.2-positive Gastric Adenocarcinoma, CLDN18.2-positive Adenocarcinoma of the Gastroesophageal Junction
Safety and Activity of IMAB362 in Combination With Zoledronic Acid and Interleukin-2 in CLDN18.2-positive Gastric Cancer
The purpose of the trial is to assess the immunological effects and their kinetics, the safety and activity of IMAB362 plus Zoledronic acid with/without low to intermediate doses of Interleukin-2 in subjects with advanced…
- Conditions
- CLDN18.2-positive Gastric Adenocarcinoma, CLDN18.2-positive Adenocarcinoma of the Gastroesophageal Junction, CLDN18.2-positive Adenocarcinoma of Esophagus
- Trial name
- PILOT (NCT01671774)
- Testing
- IMAB362, Zoledronic acid, Interleukin-2 (1 million IU)
- Where
- 9 sites in Germany, Latvia
- Volunteers
- 29 people
- Sponsor
- Astellas Pharma Global Development, Inc.
Achalasia, Paraesophageal Hernia
Minimally Invasive Surgery of the Gastro-esophageal Junction
This study will assess short and long term outcomes of individuals undergoing minimally invasive surgery of the gastro-esophageal junction (MISGEJ).
- Conditions
- Achalasia, Paraesophageal Hernia, GERD, Epiphrenic Diverticula
- Trial name
- MISGEJ (NCT01799967)
- Where
- Canada
- Volunteers
- 200 people
- Sponsor
- Ottawa Hospital Research Institute
Esophageal Squamous Cell Cancer, Adenocarcinoma of Esophagogastric Junction, Gastric Adenocarcinoma
Tucidinostat Plus PD-1 Inhibitor and Bevacizumab for Advanced Esophagus Cancer, AEG, Gastric Cancer
This Phase II study was designed to assess the efficacy and safety of the combination of PD-1 inhibitor, Tucidinostat (chidamide), a histone deacetylase inhibitor, and bevacizumab in advanced Esophageal squamous cell cancer…
- Trial name
- NCT05163483
- Testing
- Tucidinostat (chidamide), PD-1 inhibitor (Toripalimab), Bevacizumab
- Where
- China
- Volunteers
- 87 people
- Sponsor
- Ruihua Xu
Esophageal Cancer
Cisplatin, Irinotecan, and Radiation Therapy in Treating Patients With Esophageal Cancer or Gastroesophageal Junction Cancer That Can Be Removed By Surgery
This phase II trial studies how well giving cisplatin and irinotecan hydrochloride together with radiation therapy works in treating patients with esophageal cancer or gastroesophageal junction cancer that can be removed by…
- Trial name
- NCT00316862
- Testing
- cisplatin, irinotecan hydrochloride, therapeutic conventional surgery
- Where
- 24 sites in United States
- Volunteers
- 82 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Gastric Cancer (GC) Gastroesophageal Junction Cancer (GEJ)
Continuation of Serplulimab Plus Chemotherapy After First Progression in Advanced Gastric or Gastro-oesophageal Junction Adenocarcinoma: an Open-label, Randomised Phase II Trial
This study is conducted in patients with advanced metastatic gastric cancer including gastroesophageal junction cancer(patients with HER2 negative and PD-L1 CPS≥5).Patiens will recevie Serplulimab plus chemotherapy…
- Trial name
- NCT05942573
- Testing
- Serplulimab+Paclitaxel+Apatinib, Paclitaxel±Ramucirumab
- Where
- China
- Volunteers
- 107 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Gastric Cancer
Trial of Panitumumab Cisplatin, Fluourouracil and Docetaxel in Locally Advanced or Metastatic Gastric Cancer
Investigators propose to study the effect of panitumumab when combined with an active regimen, such as DCF (Docetaxel/Cisplatin/Fluourouracil), in previously untreated patients with advanced cancer of the stomach.
- Trial name
- NCT01716546
- Testing
- Pazopanib
- Where
- 9 sites in Greece
- Volunteers
- 51 people
- Sponsor
- Hellenic Oncology Research Group
Gastric Cancer, Esophageal Cancer
Comparison of Molecular-Genetic Concordance of the Primary Tumor and Brain Metastases of Gastroesophageal Cancers
GENCONCOR-2 is a translational research aimed to compare the molecular profile of primary tumors and their matched brain metastases in gastroesophageal cancers, including cancer of the esophagus, gastroesophageal junction, and…
- Conditions
- Gastric Cancer, Esophageal Cancer, Brain Metastases
- Trial name
- GENCONCOR-2 (NCT07464470)
- Testing
- HER2 Testing, MSI Testing, PD-L1 Testing
- Where
- Russia
- Volunteers
- 30 people
- Sponsor
- Blokhin's Russian Cancer Research Center
Advanced Gastric Cancer/Gastroesophageal Junction Adenocarcinoma and Other Solid Tumors
Safety and Efficacy of Glumetinib Combined With Docetaxel for Injection (Albumin-bound) in Patients With Advanced Gastric Cancer/Gastroesophageal Junction Adenocarcinoma and Other Solid Tumors
The trial consists of Stage 1 (including dose escalation and dose expansion) and Stage 2 (proof-of-concept study). Among them, Stage 2 adopts a randomized, controlled, open-label, and multicenter design.
- Trial name
- NCT06947291
- Testing
- Glumetinib Tablets, Docetaxel for Injection (Albumin-bound)
- Where
- China
- Volunteers
- 350 people
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Pharmacokinetics of Zolbetuximab, Gastric Cancer
A Study of Zolbetuximab (IMAB362) in Adults With Gastric Cancer
Zolbetuximab is being studied as a treatment for people with cancer in and around the stomach or cancer where the food pipe (esophagus) joins the stomach (gastroesophageal junction cancer).
- Conditions
- Pharmacokinetics of Zolbetuximab, Gastric Cancer, Gastro-esophageal Junction (GEJ) Cancer, Pharmacokinetics of Oxaliplatin
- Trial name
- ILUSTRO (NCT03505320)
- Testing
- zolbetuximab, oxaliplatin, leucovorin
- Where
- 21 sites in United States, France and 4 more
- Volunteers
- 143 people
- Sponsor
- Astellas Pharma Global Development, Inc.
Gastric Carcinoma
A Study of Disitamab Vedotin Combined With Tislelizumab and Chemotherapy Versus Tislelizumab Combined With Chemotherapy in HER2-Low Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
The purpose of this study is to evaluate the efficacy and safety of Disitamab Vedotin combined with Tislelizumab and CAPOX versus Tislelizumab combined with CAPOX as first-line treatment for patients with HER2-low advanced…
- Trial name
- NCT06944496
- Testing
- Disitamab Vedotin+Tislelizumab+Oxaliplatin+Capecitabine, Tislelizumab+Oxaliplatin+Capecitabine
- Where
- China
- Volunteers
- 616 people
- Sponsor
- RemeGen Co., Ltd.
Gastric Cancer
A Phase Ib/II Study of Adebrelimab in Combination with Capecitabine and Oxaliplatin in Cancer
In this study, the combination of Adebrelimab (PD-L1 monoclonal antibody) on the basis of standard treatment (two-drug chemotherapy regimen of fluorouracil and platinum drugs) may enhance the immune response in order to enhance…
- Trial name
- GC-Ib/II (NCT06776770)
- Testing
- Adebrelimab
- Where
- China
- Volunteers
- 52 people
- Sponsor
- Cancer Hospital Chinese Academy of Medical Science, Shenzhen Center
Adenocarcinoma of Esophagogastric Junction
Transhiatal/Transabdominal Approach Compare With Thoracoabdominal Approach for Siewert II Adenocarcinoma of Esophagogastric Junction
To compare transhiatal / transabdominal approach with thoracoabdominal approach for Siewert II adenocarcinoma of esophagogastric junction
- Trial name
- NCT04910789
- Testing
- transhiatal/transabdominal approach, thoracoabdominal approach
- Where
- China
- Volunteers
- 312 people
- Sponsor
- Chinese PLA General Hospital
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.